TBPH · Theravance Biopharma, Inc.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Quarter-end cash balance | $395M | Q1 2026 | — |
| TRELEGY global net sales | $873M | Q1 2026 | — |
|
|
|||
| TRELEGY global net sales year-over-year growth | 2% | Q1 2026 | — |
| YUPELRI customer demand growth | 4% | Q1 2026 | — |
| YUPELRI Annual U.S. net sales | $266.6M | full year 2025 | — |
| YUPELRI net sales | $266.6M | FY 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TBPH
this stock
Theravance Biopharma, Inc.
|
$871.25M | -9.7% | -68.4% | 7.7 | 8.4% |
|
ONC
BeOne Medicines Ltd.
|
$484.13B | +7.8% | +22179.2% | 744.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.89B | +6.9% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.13B | -0.2% | +20.8% | 19.0 | 3.4% |
|
ARGX
Argenx SE
|
$54.76B | +3.2% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TBPH | +0.3% | -0.6% | -13.4% | +0.2% | -9.7% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -5.2% | -3.9% | -24.6% | -2.8% | -22.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.